Anzeige
Mehr »
Login
Dienstag, 04.03.2025 Börsentäglich über 12.000 News von 689 internationalen Medien
Trumps Krypto-Reserve löst Markt-Explosion aus - Pioneer AI Foundry setzt auf Solana!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QK1R | ISIN: KYG4987A1094 | Ticker-Symbol: 77V
Stuttgart
03.03.25
08:07 Uhr
0,304 Euro
+0,026
+9,35 %
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
JACOBIO PHARMACEUTICALS GROUP CO LTD Chart 1 Jahr
5-Tage-Chart
JACOBIO PHARMACEUTICALS GROUP CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,2760,31003.03.
0,2740,30403.03.

Aktuelle News zur JACOBIO PHARMACEUTICALS GROUP Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.01.JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT THE REGISTRATIONAL CLINICAL DATA OF KRAS INHIBITOR GLECIRASIB WAS PUBLISHED IN THE MEDICAL JOURNAL NATURE MEDICINE1
09.12.24 JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT JACOBIO PRESENTED THE PRELIMINARY CLINICAL DATA OF BET INHIBITOR JAB-8263 TO TREAT MYELOFIBROSIS AT THE 2024 ...-
25.11.24JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT JACOBIO COMPLETED FIRST PATIENT DOSAGE IN THE PHASE I/IIA CLINICAL TRIAL OF PAN-KRAS INHIBITOR JAB-23E73 IN ...1
21.10.24JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT GLECIRASIB FOR THE TREATMENT OF PANCREATIC CANCER HAS BEEN GRANTED ORPHAN DRUG DESIGNATION IN EUROPE1
18.10.24JACOBIO-B (01167): NEXT DAY DISCLOSURE RETURN-
09.10.24JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT JACOBIO PRESENTED THE PRE-CLINICAL DATA OF SHP2 INHIBITOR JAB-3312 IN COMBINATION WITH KRAS G12C INHIBITOR GLECIRASIB ...-
08.10.24JACOBIO-B (01167): NEXT DAY DISCLOSURE RETURN-
JACOBIO PHARMACEUTICALS GROUP Aktie jetzt für 0€ handeln
03.10.24JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT JACOBIO TO PRESENT THE CLINICAL DATA OF BET INHIBITOR JAB-8263 AT THE 2024 66TH AMERICAN SOCIETY OF HEMATOLOGY ...1
27.09.24JACOBIO-B (01167): 2024 INTERIM REPORT-
27.09.24JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVED UPFRONT PAYMENT UPON THE ENTRY INTO EXCLUSIVE LICENSING-OUT AGREEMENT FOR GLECIRASIB AND JAB- ...1
26.09.24JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVED CHINA CDE INVESTIGATIONAL NEW DRUG CLEARANCE FOR PAN-KRAS INHIBITOR JAB-23E731
23.09.24JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVED INVESTIGATIONAL NEW DRUG (IND) APPROVAL FROM THE U.S. FDA FOR PAN-KRAS INHIBITOR JAB-23E731
25.06.24XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 25.06.2024558The following instruments on XETRA do have their first trading 25.06.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.06.2024 Aktien 1 US76657Y1010 Rightmove PLC ADR 2...
► Artikel lesen
02.06.24Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO220BEIJING and SHANGHAI and CHICAGO, June 1, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C...
► Artikel lesen
29.03.24Jacobio Pharma Announces 2023 Annual Results199BEIJING, SHANGHAI and BOSTON, March 28, 2024 Jacobio/PRNewswire/ -- Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results....
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1